Looking Ahead to the Future of Multiple Myeloma Treatment
Nina Shah, MD, looks to the future of treating patients with multiple myeloma.
EP: 1.Breakthroughs in Therapeutic Options for Relapsed/Refractory Multiple Myeloma
EP: 2.Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
EP: 3.Upcoming Abstracts on Multiple Myeloma for Presentation at 2021 ASH
EP: 4.Biggest FDA News for Multiple Myeloma in 2021
EP: 5.Treatment Options for Transplant-Eligible Multiple Myeloma
EP: 6.Treatment Options for Transplant-Ineligible Multiple Myeloma
EP: 7.Navigating Individual Treatment for Relapsed/Refractory Multiple Myeloma
EP: 8.Understanding Adverse Events in Multiple Myeloma
EP: 9.BCMA-Directed Agents for Multiple Myeloma
EP: 10.Optimal Therapies for Relapsed/Refractory Multiple Myeloma
EP: 11.Emerging Research and Therapies for Multiple Myeloma
EP: 12.Upcoming Phase 3 Data in Multiple Myeloma
EP: 13.Trials Evaluating Emerging Maintenance Therapy Regimens in Multiple Myeloma
EP: 14.Looking Ahead to the Future of Multiple Myeloma Treatment
EP: 15.Current Leading Therapies for Multiple Myeloma
Nina Shah, MD: As we move forward in multiple myeloma, I’m excited to see longer term follow-up data for the immunotherapy trials because it’s important for us to know what kind of duration of response our patients are going to get. I am interested in seeing quality of life data because I want to know how to choose between these modalities, which may not be the best for one patient versus another, or what may be best suited for all patients. I also want to see how we’re incorporating minimal residual disease [MRD] for decision making. For that, we’ll look to trials like the MASTER trial [NCT03224507]. Finally, I’m really excited to see if there’s some way that we could get blood-based MRD testing, which is already being looked at with mass spectrometry and other technologies, because I would love for patients to be able to avoid bone marrow [biopsies]. I hate ordering them and patients hate getting them and it’d be great if we could use something else to detect disease and detect it early.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
